Display options
Cite
Dogan HO, Ersan EE, Aydin H, et al. Thiol Disulfide Homeostasis in Schizophrenic Patients Using Atypical Antipsychotic Drugs. Clin Psychopharmacol Neurosci. 2018;16(1):39-45doi: 10.9758/cpn.2018.16.1.39.
Dogan, H. O., Ersan, E. E., Aydin, H., Erdoğan, S., Erşan, S., Alişik, M., Bakir, S., Erel, �. �., & Koç, D. (2018). Thiol Disulfide Homeostasis in Schizophrenic Patients Using Atypical Antipsychotic Drugs. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 16(1), 39-45. https://doi.org/10.9758/cpn.2018.16.1.39
Dogan, Halef Okan, et al. "Thiol Disulfide Homeostasis in Schizophrenic Patients Using Atypical Antipsychotic Drugs." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 16,1 (2018): 39-45. doi: https://doi.org/10.9758/cpn.2018.16.1.39
Dogan HO, Ersan EE, Aydin H, Erdoğan S, Erşan S, Alişik M, Bakir S, Erel Ö, Koç D. Thiol Disulfide Homeostasis in Schizophrenic Patients Using Atypical Antipsychotic Drugs. Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):39-45. doi: 10.9758/cpn.2018.16.1.39. PMID: 29397665; PMCID: PMC5810441.
Copy Download .nbib Format: NLM
Share it on

Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):39-45. doi: 10.9758/cpn.2018.16.1.39.

Thiol Disulfide Homeostasis in Schizophrenic Patients Using Atypical Antipsychotic Drugs.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Halef Okan Dogan, Etem Erdal Ersan, Hüseyin Aydin, Serpil Erdoğan, Serpil Erşan, Murat Alişik, Sevtap Bakir, Özcan Erel, Derya Koç

Affiliations

  1. Department of Biochemistry, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.
  2. Department of Psychiatry, Sivas Numune Hospital, Sivas, Turkey.
  3. Department of Clinical Biochemistry, Ankara Ataturk Education and Research Hospital, Ankara, Turkey.

PMID: 29397665 PMCID: PMC5810441 DOI: 10.9758/cpn.2018.16.1.39

Abstract

OBJECTIVE: Schizophrenia is a severe, debilitating mental disorder characterized by behavioral abnormalities. Although several studies have investigated the role of oxidative stress and the effects of antipsychotic drugs on oxidative markers in schizophrenia, adequate information is not available on these issues. The aim of this study is to determine the changes in oxidative status and thiol disulfide homeostasis in schizophrenic patients using atypical antipsychotic drugs.

METHODS: Thirteen schizophrenic patients using atypical antipsychotic drugs and 30 healthy controls were included this study. The concentrations of total oxidant status (TOS), total antioxidant status (TAS), native thiol, total thiol, and disulfide levels were determined in the study population.

RESULTS: The TAS (

CONCLUSION: These results may suggest that atypical antipsychotic drugs have a useful therapeutic effect by reducing oxidative stress via the inhibition of the formation of disulfide bonds. The study population number was one of the limitations of this study. Therefore, further studies are needed to establish the association between thiol disulfide homeostasis in schizophrenic patients using atypical antipsychotic drugs.

Keywords: Antipsychotics; Disulfides; Schizophrenia; Thiols

References

  1. Front Behav Neurosci. 2014 Oct 06;8:343 - PubMed
  2. Neuropsychobiology. 2004;49(4):205-9 - PubMed
  3. J Psychiatr Res. 2007 Aug;41(5):372-86 - PubMed
  4. Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):288-95 - PubMed
  5. Neuropsychobiology. 2009;59(1):8-11 - PubMed
  6. Clin Biochem. 2014 Dec;47(18):326-32 - PubMed
  7. Free Radic Biol Med. 2009 Nov 15;47(10):1329-38 - PubMed
  8. Psychiatry Res. 2015 Sep 30;229(1-2):200-5 - PubMed
  9. J Neurosci Res. 2003 Aug 1;73(3):364-8 - PubMed
  10. Clin Chem Lab Med. 2016 Mar;54(3):447-52 - PubMed
  11. Clin Biochem. 2004 Apr;37(4):277-85 - PubMed
  12. J Biol Chem. 2013 Sep 13;288(37):26489-96 - PubMed
  13. Schizophr Res Treatment. 2012;2012:373261 - PubMed
  14. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16621-6 - PubMed
  15. Clin Biochem. 2005 Dec;38(12):1103-11 - PubMed
  16. Prostaglandins Leukot Essent Fatty Acids. 2003 Dec;69(6):393-9 - PubMed
  17. Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):275-82 - PubMed
  18. Eur Neuropsychopharmacol. 2006 Dec;16(8):588-91 - PubMed
  19. BMC Psychiatry. 2011 Aug 02;11:124 - PubMed
  20. Psychiatry Clin Neurosci. 2006 Aug;60(4):458-64 - PubMed
  21. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):155-9 - PubMed
  22. Clin Biochem. 2007 Sep;40(13-14):1026-31 - PubMed
  23. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Sep;29(7):1181-91 - PubMed
  24. Clin Chem Lab Med. 2000 Dec;38(12):1277-81 - PubMed
  25. Psychiatry Res. 2016 Jun 30;240:222-225 - PubMed
  26. PLoS One. 2008 Apr 09;3(4):e1944 - PubMed
  27. Psychiatry Res. 2010 Aug 30;179(1):24-9 - PubMed
  28. Psychiatry Clin Neurosci. 2009 Oct;63(5):693-700 - PubMed
  29. Neurosci Res. 2011 Dec;71(4):335-40 - PubMed
  30. J Pak Med Assoc. 2015 Feb;65(2):131-5 - PubMed
  31. Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):36-47 - PubMed
  32. Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):68-82 - PubMed
  33. Neuropsychobiology. 2009;60(2):87-93 - PubMed
  34. Int J Clin Exp Med. 2014 Apr 15;7(4):1089-93 - PubMed
  35. Neuropsychobiology. 2009;59(1):1-7 - PubMed
  36. Dis Markers. 2006;22(1-2):83-93 - PubMed
  37. J Psychiatr Res. 2003 Jan-Feb;37(1):43-51 - PubMed
  38. Nat Rev Drug Discov. 2011 Mar;10(3):209-19 - PubMed
  39. Curr Neuropharmacol. 2011 Jun;9(2):301-12 - PubMed
  40. Int J Neuropsychopharmacol. 2008 Sep;11(6):851-76 - PubMed
  41. Psychiatr Clin North Am. 2007 Sep;30(3):323-38 - PubMed

Publication Types